BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.30
+2.16 (2.91%)
At close: Dec 19, 2025, 4:00 PM EST
76.30
0.00 (0.00%)
After-hours: Dec 19, 2025, 7:59 PM EST
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 21 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $76.24, which forecasts a -0.08% decrease in the stock price over the next year. The lowest target is $49 and the highest is $110.
Price Target: $76.24 (-0.08%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 9 | 9 | 9 |
| Buy | 9 | 9 | 9 | 9 | 10 | 12 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 18 | 19 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $75 → $86 | Buy | Maintains | $75 → $86 | +12.71% | Dec 15, 2025 |
| Bernstein | Bernstein | Buy Initiates $94 | Buy | Initiates | $94 | +23.20% | Dec 11, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $76 → $84 | Buy | Maintains | $76 → $84 | +10.09% | Nov 11, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $76 → $77 | Buy | Maintains | $76 → $77 | +0.92% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +17.96% | Nov 3, 2025 |
Financial Forecast
Revenue This Year
506.91M
from 221.90M
Increased by 128.44%
Revenue Next Year
892.89M
from 506.91M
Increased by 76.14%
EPS This Year
-3.55
from -2.88
EPS Next Year
-1.86
from -3.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 593.7M | 1.3B | ||||
| Avg | 506.9M | 892.9M | ||||
| Low | 447.3M | 568.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 167.5% | 156.7% | ||||
| Avg | 128.4% | 76.1% | ||||
| Low | 101.6% | 12.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.19 | -0.71 | ||||
| Avg | -3.55 | -1.86 | ||||
| Low | -3.59 | -2.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.